drugset

drugset / Trial / NCT02531568

Drug Interaction Study of Warfarin and MT-3995

NCT02531568 ↗

Phase 1 Completed 20 enrolled Tanabe Pharma Corporation

CrossoverOpen-labelScreening

Summary

The purpose of this study is to evaluate the effects of MT-3995 on the PK of warfarin

Timeline

Start: 2015-06
Primary completion: 2015-08
Completion: 2015-09

Publications

Nakamura T, Shimizu H, Kawaguchi A. Drug-Drug Interactions of the Nonsteroidal Mineralocorticoid Receptor Antagonist Apararenone With Midazolam, Warfarin, and Digoxin: A Phase 1 Studies in Healthy Volunteers. Clin Ther. 2020 Nov;42(11):2171-2183.e4. doi: 10.1016/j.clinthera.2020.09.002. Epub 2020 Nov 3.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	MT-3995	Small molecule	10 mg	—
Subject	Warfarin	Small molecule	25 mg	—

Indications

No indication recorded.